Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Platzer on a combined asset swap transaction with the Port of Gothenburg concerning properties in Arendal

Vinge has advised Platzer on a combined asset swap transaction with the Port of Gothenburg comprising the sale of the property Arendal 1:28, parts of the properties Arendal 1:29 and Arendal 1:31, and the acquisition of part of the property Arendal 764:291.
April 08, 2026

Vinge has advised SEB, Swedbank and Danske Bank in connection with a bridge facility to Catena

Vinge has advised Skandinaviska Enskilda Banken AB (publ), Swedbank AB (publ) and Danske Bank A/S in their capacities as mandated lead arrangers and bookrunners in connection with a term loan bridge facility in an aggregate amount of SEK 4,360,000,000, EUR 195,000,000 and DKK 170,000,000 to Catena AB (publ).
April 02, 2026

Vinge advises the founders of Nordic Knots in connection with the investment in the company by Imaginary Ventures and other investors

Vinge has advised the founders of Nordic Knots in connection with an investment in the company led by Imaginary Ventures, with additional investors including Creades, IRIS Ventures and St Dominique Capital.
April 02, 2026